The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35
Apr 12, 2024
31:27
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies.
Talking Precision Medicine